Clinical Practice Guidelines

The Nova Scotia guidelines for antenatal laboratory screening and testing were revised and re-released in June 2015. The guidelines are available in a convenient printable card format. The companion document to the new Nova Scotia Prenatal Record provides detailed information on applying these guidelines.

The authors of Alcohol Use and Pregnancy, Consensus Clinical Guidelines, published by the SOGC in 2010, say "...there is evidence that alcohol consumption in pregnancy can cause fetal harm ... there is insufficient evidence regarding fetal safety or harm at low levels of alcohol consumption in pregnancy ... there is insufficient evidence to define any threshold for low-level drinking in pregnancy."

They recommend that "... universal screening for alcohol consumption should be done periodically for all pregnant women and women of child-bearing age. Ideally, at-risk drinking could be identified before pregnancy, allowing for change."

The full guideline along with summarized statements and recommendations is available at: http://sogc.org/guidelines/alcohol-use-and-pregnancy-consensus-clinical-guidelines

Pre-term birth is a significant health issue in Canada. In an effort to avoid unnecessary antepartum admissions or maternal transfers, many jurisdictions have adopted Fetal Fibronectin (ƒFN) testing for women with symptoms of pre-term labour. To assist health-care professionals and planners with the implementation and monitoring of a testing program, a Working Group with representatives from across Canada developed the following resources: a clinical guideline, a presentation, and a list of key indicators. These documents are provided as templates and can be adapted based on local circumstances.
RCP worked in collaboration with regional hospitals across Nova Scotia in 2006 to implement fetal fibronectin (fFN) testing to diagnose preterm labour. Dr. Heather Scott, Obstetrical Co-Director of RCP, Rebecca Attenborough, Coordinator RCP, and Mike Mahaffa, Adeza Biomedical Representative gave a presentation via telehealth on the implementation and use of fFN in Nova Scotia.